Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics
Rattachement africain : ca, us, gb, sg, tw, au, it, ar, se, pl, be, nl, bg, co, dk, ee, fr, gr, ie, jp, kw, mx, no, pt, sa, kr, es, ae. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Rationale Although clinical trials have documented the oral corticosteroid (OCS)-sparing effect of biologics in patients with severe asthma, little is known about whether this translates to a reduction of new-onset OCS-related adverse outcomes. Objectives To compare the risk of developing new-onset OCS-related adverse outcomes between biologic initiators and noninitiators. Methods This was a longitudinal cohort study using pooled data from the International Severe Asthma Registry (ISAR; 16 countries) and the Optimum Patient Care Research database (OPCRD; United Kingdom). For biologic initiators, the index date was the date of biologic initiation. For noninitiators, it was the date of enrollment (for ISAR) or a random medical appointment date (for OPCRD). Inverse probability of treatment weighting was used to improve comparability between groups, and weighted Cox proportional hazard models were used to estimate the hazard ratios (HRs) of developing OCS-related adverse outcomes for up to 5 years from the index date. Measurements and Main Results A total of 42,908 patients were included. Overall, 27.3% and 4.7% of biologic initiators and noninitiators were long-term OCS users (daily intake ⩾90 consecutive days in year before the index date), with a mean prednisolone-equivalent daily dose of 10.2 mg and 6.2 mg, respectively. Compared with noninitiators, biologic initiators had decreased rate of developing any OCS-related adverse outcome (HR [95% confidence interval (CI)]: 0.82 [0.72–0.93]; P = 0.002), primarily driven by reduced rate of developing diabetes (0.62 [0.45–0.87]; P = 0.006), major cardiovascular events (0.65 [0.44–0.97]; P = 0.034), and anxiety and/or depression (0.68 [0.55–0.85]; P = 0.001). There were no significant differences in the rates of new-onset cataract (HR, 0.77 [95% CI, 0.47–1.25]), sleep apnea (HR, 0.82 [95% CI, 0.78–1.41]), or other OCS-related adverse outcomes assessed (e.g., osteoporosis). The results were consistent across both datasets. Conclusions Our findings highlight the role for biologics in preventing new-onset OCS-related adverse outcomes in patients with severe asthma.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics
- Date Crossref
- 01/07/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of British Columbia pays non établi dans la noticeUniversité ou école supérieure
-
AstraZeneca (United States) pays non établi dans la noticeEntreprise
-
Care UK (United Kingdom) pays non établi dans la noticeEntreprise
-
Observational & Pragmatic Research Institute pays non établi dans la noticeInstitution
-
Optimum Patient Care pays non établi dans la noticeOrganisation à but non lucratif
-
Kaohsiung Medical University Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Kaohsiung Medical University Chung-Ho Memorial Hospital pays non établi dans la noticeÉtablissement de santé
-
Queen's University Belfast Wellcome-Wolfson Institute for Experimental Medicine pays non établi dans la noticeUniversité ou école supérieure
-
UNSW Sydney pays non établi dans la noticeUniversité ou école supérieure
-
The George Institute for Global Health Head Respiratory Group pays non établi dans la noticeStructure de recherche
-
National Jewish Health pays non établi dans la noticeÉtablissement de santé
-
ENT and Allergy pays non établi dans la noticeÉtablissement de santé
University of British Columbia, AstraZeneca (United States) et Care UK (United Kingdom), avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.